PharmaCyte Biotech Statistics
Share Statistics
PharmaCyte Biotech has 6.86M
shares outstanding. The number of shares has increased by -18.81%
in one year.
| Shares Outstanding | 6.86M |
| Shares Change (YoY) | -18.81% |
| Shares Change (QoQ) | -1.5% |
| Owned by Institutions (%) | 7.86% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 200 |
| FTD / Avg. Volume | 1.46% |
Short Selling Information
The latest short interest is 4.04K, so 0.06% of the outstanding
shares have been sold short.
| Short Interest | 4.04K |
| Short % of Shares Out | 0.06% |
| Short % of Float | 0.06% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is 60.86 and the forward
PE ratio is null.
PharmaCyte Biotech's PEG ratio is
0.08.
| PE Ratio | 60.86 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.51 |
| P/FCF Ratio | -9.44 |
| PEG Ratio | 0.08 |
Financial Ratio HistoryEnterprise Valuation
PharmaCyte Biotech has an Enterprise Value (EV) of -29.87M.
| EV / Sales | 0 |
| EV / EBITDA | 0 |
| EV / EBIT | 13.88 |
| EV / FCF | 13.88 |
Financial Position
The company has a current ratio of 6.8,
with a Debt / Equity ratio of 0.
| Current Ratio | 6.8 |
| Quick Ratio | 6.8 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 0.84% and Return on Invested Capital is -12.42%.
| Return on Equity | 0.84% |
| Return on Assets | 0.56% |
| Return on Invested Capital | -12.42% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $166,881.5 |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -50.24% in the
last 52 weeks. The beta is -0.43, so PharmaCyte Biotech's
price volatility has been lower than the market average.
| Beta | -0.43 |
| 52-Week Price Change | -50.24% |
| 50-Day Moving Average | 1.28 |
| 200-Day Moving Average | 1.61 |
| Relative Strength Index (RSI) | 36.15 |
| Average Volume (20 Days) | 13,740 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6.52M |
| Net Income | 333.76K |
| EBITDA | n/a |
| EBIT | -6.52M |
| Earnings Per Share (EPS) | -1.8 |
Full Income StatementBalance Sheet
The company has 50.18M in cash and 0 in
debt, giving a net cash position of 50.18M.
| Cash & Cash Equivalents | 50.18M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -115.63M |
| Total Assets | 43.83M |
| Working Capital | 15.77M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -2.15M
and capital expenditures 0, giving a free cash flow of -2.15M.
| Operating Cash Flow | -2.15M |
| Capital Expenditures | n/a |
| Free Cash Flow | -2.15M |
| FCF Per Share | -0.22 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
